Senolytic treatment improved motor function and reduced neuronal damage in TDP-43 ALS mice
This animal study investigated cellular senescence in TDP-43Q331K mice, a genetic model of amyotrophic lateral sclerosis. Researchers treated mice with dasatinib and quercetin (senolytics) and found improvements in motor behavior, neuromuscular function, reduced axonal damage measured by plasma neurofilament light chain, enhanced motor cortex excitability, and preserved layer V neuron counts compared to controls.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 18, 2026 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Preclinical
- Sample size
- —
- Duration
- —
- Population
- TDP-43Q331K mice (genetic ALS model)
- Primary outcome
- Markers of cellular senescence in motor cortex and spinal cord; motor behavior; neuromuscular function; axonal damage (plasma neurofilament light chain)
- Effect size
- —
- Significance
- Significant
- Journal
- Neurobiology of disease
- Published
- Sep 18, 2026
Sources
Primary source
- Neurobiology of disease ↗Peer reviewed
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.